Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians

← catalyst calendar

NCT07682363 · readout in 188 d

Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.

Phase

—

Status

Recruiting

Study type

Observational

Enrollment

470estimated

Sites

Country

China

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-06-03

actual

When the study began enrolling

Primary completion

2027-02-23

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-02-23

estimated

The whole study's end, after follow-up

First posted

2026-07-02

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-02

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Liver Disease

Intervention

Other: No treatment is given

Primary outcomes

what the primary-completion date above is the date OF

To investigate attitudes and perceptions concerning the reasons for further severity assessment (mainly refers to the assessment of liver fibrosis) following a MASLD diagnosis